Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad. Read more: https://www.biopharma-reporter.com/Article/2018/08/15/US-FDA-approves-first-non-gene-edited-allogeneic-CAR-T-cell-candidate-for-trials?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyrightContinue Reading

Continuous therapy with lenalidomide may lead to the greatest improvements in survival outcomes among patients with newly diagnosed multiple myeloma (NDMM) compared with other regimens in the maintenance setting, according to a study published in JAMA Oncology.1 Many agents have demonstrated efficacy as maintenance agents in patients with NDMM. Due to a lack of comparative...Continue Reading